Ignite Creation Date:
2024-05-06 @ 4:33 PM
Last Modification Date:
2024-10-26 @ 2:12 PM
Study NCT ID:
NCT05027373
Status:
UNKNOWN
Last Update Posted:
2021-08-30
First Post:
2021-08-17
Brief Title:
Safety Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection
Sponsor:
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Organization:
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-08-13
Start Date Type:
ACTUAL
Primary Completion Date:
2022-04-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2022-09-30
Completion Date Type:
ESTIMATED
First Submit Date:
2021-08-17
First Submit QC Date:
August 27 2021
Study First Post Date:
2021-08-30
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-08-27
Last Update Post Date:
2021-08-30
Last Update Post Date Type:
ACTUAL